Amicus receives growth capital from HBM Healthcare Investments
6 July 2017 – HBM Healthcare Investments invested EUR 20 million into the privately held and Switzerland based Amicus SA. The financing will allow Amicus to accelerate the growth of its pharmaceutical business in Central and Eastern Europe (CEE).
Walder Wyss acted as advisor in all legal aspects of the transaction. The team was led by Markus Vischer (Partner, Corporate/M&A) and further included Christian Hagen (Associate, Corporate/M&A), Samuel Lieberherr (Associate, Corporate/M&A), Thomas Meister (Partner, Tax) and Christoph Stutz (Associate, Employment).